Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells

Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells

Abstract Background Pancreatic cancer (PC) is the fourth most common cause of cancer death. Combination therapies with classical chemotherapeutic agents improved treatment of advanced PC at the cost of a relevant toxicity, but the 5-year survival rate remains below 5%. Consequently, new therapeutic...

Full description

Bibliographic Details
Main Authors: Serena Veschi, Laura De Lellis, Rosalba Florio, Paola Lanuti, Alberto Massucci, Nicola Tinari, Michele De Tursi, Pierluigi di Sebastiano, Marco Marchisio, Clara Natoli, Alessandro Cama
Format: Article
Language:English
Published: BMC 2018-09-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Pancreatic ductal adenocarcinoma
PDAC
Drug repositioning
Drug combinations
Colony formation
Combination index
Online Access:http://link.springer.com/article/10.1186/s13046-018-0904-2

Internet

http://link.springer.com/article/10.1186/s13046-018-0904-2

Similar Items